PT  - JOURNAL ARTICLE
AU  - Junhua Liu
AU  - Huping Jiao
AU  - Xiushan Yin
TI  - Engineered human mesenchymal stem cells as new vaccine platform for COVID-19
AID  - 10.1101/2020.06.20.163030
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.06.20.163030
4099  - http://biorxiv.org/content/early/2020/06/20/2020.06.20.163030.short
4100  - http://biorxiv.org/content/early/2020/06/20/2020.06.20.163030.full
AB  - Recently, there are several routes for COVID-19 vaccine research, yet their weaknesses lie in low efficiency, tolerability, immune adaptability and safety. We describe a new approach to COVID-19 based on engineered human mesenchymal stem cells(hu-MSC), which is like a small protein antigen response device, but will be gradually cleared and degraded by body’s immune system among recognization process. The antibody response results show that this is effective and fast. Furthermore, after several antibody response tests, we obtained an injection of a set of cocktail-like modified human mesenchymal stem cell line. This strategy opened a new avenue for vaccine design against COVID-19.Competing Interest StatementXiushan Yin and Junhua Liu had filled a PCT patent related to MSC-vaccine against COVID-19